Filtered By:
Therapy: Statin Therapy
Nutrition: Calcium

This page shows you your search results in order of date. This is page number 4.

Order by Relevance | Date

Total 76 results found since Jan 2013.

In Brief: Pitavastatin Magnesium (Zypitamag) for Hyperlipidemia
Date: June 18, 2018 Issue #:  1549Summary:  The FDA has approved the HMG-CoA reductase inhibitor (statin) pitavastatin magnesium (Zypitamag– Zydus) for use in adults with primary hyperlipidemia or mixed dyslipidemia. The FDA considers pitavastatin magnesium bioequivalent to pitavastatin calcium(Livalo), which was approved in 2009.1Statins remain the treatment of choice for most patients who require lipid-lowering therapy. Taken as an adjunct to diet modification, increased exercise, and smoking cessation, statins can reduce the risk of primary and secondary cardiovascular events and death in ...
Source: The Medical Letter - June 11, 2018 Category: Drugs & Pharmacology Authors: admin Source Type: research

Association between the   TIMD4-HAVCR1 variants and serum lipid levels, coronary heart disease and ischemic stroke risk and atorvastatin lipid-lowering efficacy.
This study aimed to determine the TIMD4-HAVCR1 variants, their haplotypes and gene-environment interactions on serum lipid levels, the risk of CHD and IS, and the lipid-lowering efficacy of atorvastatin in a southern Chinese Han population. Genotypes of 3 variants in 622 controls, 579 CHD and 546 IS patients were determined by the Snapshot technology. Atorvastatin calcium tablet (20 mg/d) was given in 724 hyperlipidemic patients for 8 weeks after genotyping. The rs12522248 genotypic and allelic frequencies were different between controls and patients, and were associated with the risk of CHD and IS. The rs1501908G-rs125222...
Source: Bioscience Reports - December 5, 2017 Category: Biomedical Science Authors: Zhang QH, Yin RX, Chen WX, Cao XL, Chen YM Tags: Biosci Rep Source Type: research

“Quackery” that saves lives
I’m used to being a target of mainstream medicine. I can’t even count the number of times I’ve been called a “quack.”  Let me give you just one example… For decades I’ve been treating my patients with a proven therapy. The FDA approved it way back in 1953. I use it to help my patients detox from mercury, lead, cadmium and other heavy metals. In fact, more than 100,000 people get this therapy every year in the U.S. But mainstream doctors still laugh at the idea of this treatment and think it’s pure bunk. I’m talking about intravenous (IV) chelation. Even though I’ve...
Source: Al Sears, MD Natural Remedies - October 5, 2017 Category: Complementary Medicine Authors: Randall Hall Tags: Anti-Aging Health Heart Health Men's Health Women's Health Source Type: news

Implications of prescribing a fixed-dose combination in clinical cardiology practice: a retrospective observational study using a single medical centre database in Korea
Conclusions FDC discontinuation was common among patients attending the cardiology outpatient clinic. Our analyses suggest that FDC discontinuation in patients at high ASCVD risk may have an impact on CV event rates.
Source: Heart Asia - June 26, 2017 Category: Cardiology Authors: Kim, H., Yoon, H.-J., Park, H.-S., Cho, Y.-K., Nam, C.-W., Han, S., Hur, S.-H., Kim, Y.-N., Kim, K.-B. Tags: Original research Source Type: research

Co-morbidity and clinically significant interactions between antiepileptic drugs and other drugs in elderly patients with newly diagnosed epilepsy
Conclusions Elderly patients with newly diagnosed epilepsy are at high risk of clinically relevant pharmacokinetic interactions with other drugs, especially if exposed to carbamazepine, but these interactions can be controlled via rational drug choices and with prediction of the possible drug-to-drug interactions. Patients on dihydropyridine calcium-channel blockers, statins, warfarin, and risperidone face the highest risk of interactions.
Source: Epilepsy and Behavior - June 14, 2017 Category: Neurology Source Type: research

Co-morbidity and clinically significant interactions between antiepileptic drugs and other drugs in elderly patients with newly diagnosed epilepsy.
CONCLUSIONS: Elderly patients with newly diagnosed epilepsy are at high risk of clinically relevant pharmacokinetic interactions with other drugs, especially if exposed to carbamazepine, but these interactions can be controlled via rational drug choices and with prediction of the possible drug-to-drug interactions. Patients on dihydropyridine calcium-channel blockers, statins, warfarin, and risperidone face the highest risk of interactions. PMID: 28622547 [PubMed - as supplied by publisher]
Source: Epilepsy and Behaviour - June 13, 2017 Category: Neurology Authors: Bruun E, Virta LJ, Kälviäinen R, Keränen T Tags: Epilepsy Behav Source Type: research

A Multimodality Strategy for Cardiovascular Risk Assessment: Performance in Two Population-Based Cohorts.
Conclusions -Among adults without known CVD, a novel multimodality testing strategy using ECG-LVH, CAC, NT-proBNP, hs-cTnT and hs-CRP significantly improved global CVD and ASCVD risk assessment. PMID: 28360032 [PubMed - as supplied by publisher]
Source: Circulation - March 30, 2017 Category: Cardiology Authors: de Lemos JA, Ayers CR, Levine BD, deFilippi CR, Wang TJ, Hundley WG, Berry JD, Seliger SL, McGuire DK, Ouyang P, Drazner MH, Budoff MJ, Greenland P, Ballantyne CM, Khera A Tags: Circulation Source Type: research

Prognostic Analysis for Cardiogenic Shock in Patients with Acute Myocardial Infarction Receiving Percutaneous Coronary Intervention.
Abstract Cardiogenic shock (CS) is uncommon in patients suffering from acute myocardial infarction (AMI). Long-term outcome and adverse predictors for outcomes in AMI patients with CS receiving percutaneous coronary interventions (PCI) are unclear. A total of 482 AMI patients who received PCI were collected, including 53 CS and 429 non-CS. Predictors for AMI patients with CS including recurrent MI, cardiovascular (CV) mortality, all-cause mortality, and repeated-PCI were analyzed. The CS group had a lower central systolic pressure and central diastolic pressure (both P < 0.001). AMI patients with hypertension h...
Source: Biomed Res - March 4, 2017 Category: Research Authors: Lin MJ, Chen CY, Lin HD, Wu HP Tags: Biomed Res Int Source Type: research

Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation
ConclusionPeripheral arterial disease is prevalent in 11% of AF patients and related to various atherosclerotic risk factors. Even if PAD is associated with higher risk of all-cause death on univariate analysis, this risk was significantly lowered and was no longer evident after adjusting for the use of CV prevention drugs.
Source: Europace - December 9, 2016 Category: Cardiology Source Type: research

Sep 30 Cardiology News Sep 30 Cardiology News
Biomarkers in patients with type 2 diabetes, coronary calcium and statin eligibility, tea and coffee, endovascular stroke therapy and healthcare reform are discussed in this week ' s podcast.theheart.org on Medscape
Source: Medscape Cardiology Headlines - September 30, 2016 Category: Cardiology Tags: Cardiology News Source Type: news

Long-Term Exposure to Ambient Fine Particulate Matter and Renal Function in Older Men: The Veterans Administration Normative Aging Study
Conclusions: In this longitudinal sample of older men, the findings supported the hypothesis that long-term PM2.5 exposure negatively affects renal function and increases renal function decline. Citation: Mehta AJ, Zanobetti A, Bind MC, Kloog I, Koutrakis P, Sparrow D, Vokonas PS, Schwartz JD. 2016. Long-term exposure to ambient fine particulate matter and renal function in older men: the VA Normative Aging Study. Environ Health Perspect 124:1353–1360; http://dx.doi.org/10.1289/ehp.1510269 Address correspondence to A.J. Mehta, Department of Environmental Health, Harvard T.H. Chan School of Public Health, Landmark Ce...
Source: EHP Research - September 1, 2016 Category: Environmental Health Authors: Web Admin Tags: Research Article September 2016 Source Type: research

Get Rid of Toxins to Reduce Risk of Stroke
Effects of Toxins I’ve been warning you about the toxins in our environment for years. They cause inflammation… They make you gain weight… They cause you to feel fatigued… Our exposure to them starts before we’re even born. One study found 287 chemicals and toxins in the blood of newborn babies.1 It’s shocking. What is in the air we breathe? We breathe in toxins and air pollutants every day. Carbon dioxide, lead, nitrogen oxide, sulfur dioxide, and particulate matter (PM). Causes of Stroke Now, a new study reveals that air pollution is responsible for as many as one-third of all strokes.2 That’...
Source: Al Sears, MD Natural Remedies - July 15, 2016 Category: Complementary Medicine Authors: Al Sears Tags: Health Source Type: news

Gene Polymorphisms Affect the Effectiveness of Atorvastatin in Treating Ischemic Stroke Patients
Background/Aims: The aim of the present study is to investigate whether the single nucleotide polymorphism (SNP) in lipid metabolism related genes would affect the effectiveness of atorvastatin in both Han and Uighur populations. Methods: 200 ischemic stroke patients were treated with atorvastatin. The differences of blood lipid level and their ratios were measured. Six lipid related genes, HMGCR, APOA5, LPL, CETP, LDLR and PCSK9 were selected as candidate genes. And nine SNP loci in these six genes were genotyped by SNaPshot technique. Results: In all patients treated with atorvastatin, the SNP rs662799 significantly affe...
Source: Cellular Physiology and Biochemistry - July 14, 2016 Category: Cytology Source Type: research

What to do when blood test results are not quite “normal”
Picture this: you’re reading the results of your recent bloodwork, and you notice some numbers are teetering on the edge of the normal range. Should you be concerned? “It’s tricky, because in some tests, a borderline result makes no difference. In others, it might indicate an important change in health that we need to follow or act on,” says geriatrician Dr. Suzanne Salamon, assistant professor at Harvard Medical School. About normal ranges and interpreting the numbers When you look at a printout of your lab results, you’ll find the normal ranges for each blood test next to your personal results. For example, if ...
Source: New Harvard Health Information - June 2, 2016 Category: Consumer Health News Authors: Heidi Godman Tags: Tests and procedures blood test Source Type: news

What to do when blood test results not quite “normal”
Picture this: you’re reading the results of your recent bloodwork, and you notice some numbers are teetering on the edge of the normal range. Should you be concerned? “It’s tricky, because in some tests, a borderline result makes no difference. In others, it might indicate an important change in health that we need to follow or act on,” says geriatrician Dr. Suzanne Salamon, assistant professor at Harvard Medical School. About normal ranges and interpreting the numbers When you look at a printout of your lab results, you’ll find the normal ranges for each blood test next to your personal results. For example, if ...
Source: New Harvard Health Information - June 2, 2016 Category: Consumer Health News Authors: Heidi Godman Tags: Tests and procedures blood test Source Type: news